Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW.

Blood. 2012 Dec 13;120(25):4921-8. doi: 10.1182/blood-2011-09-376517. Epub 2012 Oct 4. Review.

2.

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.

Karaköse S, Oruç N, Zengin M, Akarca US, Ersöz G.

Turk J Gastroenterol. 2015 Jan;26(1):42-8. doi: 10.5152/tjg.2015.5738.

3.

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Yonal I, Pinarbası B, Hindilerden F, Hancer VS, Nalcaci M, Kaymakoglu S, Diz-Kucukkaya R.

J Thromb Thrombolysis. 2012 Oct;34(3):388-96.

PMID:
22569900
4.

Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.

Qi X, Zhang C, Han G, Zhang W, He C, Yin Z, Liu Z, Bai W, Li R, Bai M, Yang Z, Wu K, Fan D.

J Gastroenterol Hepatol. 2012 Jun;27(6):1036-43. doi: 10.1111/j.1440-1746.2011.07040.x.

PMID:
22142461
5.

[Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].

Fama A, Rago A, Gioiosa F, Marzano C, Latagliata R, Mammì C, Laganà C, D'Elia GM, Bizzoni L, Trasarti S, Ferretti A, Breccia M, Riggio O, Tafuri A.

Clin Ter. 2010;161(2):169-71. Review. Italian.

PMID:
20499034
6.

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.

Qi X, Yang Z, Bai M, Shi X, Han G, Fan D.

Aliment Pharmacol Ther. 2011 May;33(10):1087-103. doi: 10.1111/j.1365-2036.2011.04627.x. Epub 2011 Mar 13.

7.

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC.

Blood. 2008 May 15;111(10):4922-9. doi: 10.1182/blood-2007-11-125328. Epub 2008 Feb 4.

8.

Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.

De Stefano V, Qi X, Betti S, Rossi E.

Thromb Haemost. 2016 Jan;115(2):240-9. doi: 10.1160/TH15-04-0326. Epub 2015 Sep 3. Review.

PMID:
26333846
9.

Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N.

Trop Gastroenterol. 2011 Oct-Dec;32(4):279-84.

PMID:
22696908
10.

Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?

Mishchenko E, Tadmor T, Schiff E, Attias D, Polliack A.

Am J Hematol. 2011 Feb;86(2):223-4. doi: 10.1002/ajh.21926.

11.

JAK2V617F mutation in patients with splanchnic vein thrombosis.

Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, Zalcberg IR, Spector N.

Dig Dis Sci. 2010 Jun;55(6):1770-7. doi: 10.1007/s10620-009-0933-y. Epub 2009 Aug 19.

PMID:
19690956
12.

Occult myeloproliferative neoplasms: not so occult any more.

Karam D, Iyer V, Agrawal B.

BMJ Case Rep. 2017 May 30;2017. pii: bcr-2017-219388. doi: 10.1136/bcr-2017-219388.

PMID:
28559287
13.

The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.

Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M, de Maat MP, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie).

Blood. 2011 Apr 14;117(15):3968-73. doi: 10.1182/blood-2010-11-319087. Epub 2011 Mar 1.

14.

JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?

Janssen HL, Leebeek FW.

Hepatology. 2006 Dec;44(6):1391-3. No abstract available.

PMID:
17133464
15.

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.

Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM.

Hepatology. 2006 Dec;44(6):1528-34.

PMID:
17133457
16.
17.

Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis.

Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Haagsma EB, Kuipers EJ, Janssen HL.

Am J Gastroenterol. 2006 Jan;101(1):83-90.

PMID:
16405538
18.

Prothrombotic disorders in abdominal vein thrombosis.

Leebeek FW, Smalberg JH, Janssen HL.

Neth J Med. 2012 Nov;70(9):400-5. Review.

19.

JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W.

Blood. 2009 May 28;113(22):5617-23. doi: 10.1182/blood-2008-12-196014. Epub 2009 Mar 9.

20.

JAK2 mutations across a spectrum of venous thrombosis cases.

Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K.

Am J Clin Pathol. 2010 Jul;134(1):82-5. doi: 10.1309/AJCP7VO4HAIZYATP.

PMID:
20551270

Supplemental Content

Support Center